Aurinia Pharmaceuticals Analyst Ratings
Aurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS Prospects
Aurinia Pharmaceuticals Analyst Ratings
Aurinia Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN) and Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals: A Buy Rating on Strong Lupkynis Sales and Streamlined Operations
Aurinia Pharmaceuticals Analyst Ratings
Aurinia Stock Downgraded by Bloom Burton Amid Strategic Challenges
Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals (AUPH) Gets a Buy From RBC Capital
H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)
Strong Sales Performance and Market Outperformance: A Buy Rating for Aurinia Pharmaceuticals
Strong 3Q Performance and Growing Lupkynis Sales Bolster Aurinia Pharmaceuticals' Buy Rating: An In-depth Analysis by David Martin, PhD
RBC Capital Sticks to Their Buy Rating for Aurinia Pharmaceuticals (AUPH)
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH) and Cerevel Therapeutics Holdings (CERE)
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $15 Price Target
Aurinia Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15
Aurinia Pharmaceuticals Analyst Ratings
No Data